Gentian Diagnostics Asa · OSL:GENT
Gentian Diagnostics Asa — Pareto Healthcare Conference 2020
17 slides from Gentian Diagnostics Asa's conference presentation, Sep 2, 2020
Slide 1: Company presentation Pareto Healthcare Conference
Company presentation Pareto Healthcare Conference September 2nd, 2020 Hilja Ibert, CEO
Slide 2: Important notice
Important notice This presentation has been prepared by and is the sole responsibility of Gentian Diagnostics AS (the “Company” or “Gentian”). The presentation is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. The in
Slide 3: Gentian Diagnostics – Corporate overview
Gentian Diagnostics – Corporate overview Acts in the life science market with global reach Headquartered in Moss, Norway NOK Listed on Merkur Market since December 2016 Shares outstanding: 15.4m Market cap end 2Q NOK 778m More than 900 shareholders Major shareholders include Vatne Capi
Slide 4: We innovate diagnostic efficiency
We innovate diagnostic efficiency
Slide 5: Efficiency gains for immunoassays
Efficiency gains for immunoassays GENTIAN PLAY Clinical chemistry 9.1BUSD 17.5B USD Moving immunoassays to clinical chemistry: Making them available for high-throughput and cost effective instruments 51.1BUSD POC, MDX, microbiology, haematology, other IVD Reagent Market 2018 65B USD/2023 78B USD CAG
Slide 6: Products and pipeline: 1 new product per year
Products and pipeline: 1 new product per year Market size Target category (USD) >1.0B GCAL® G-1001 Cystatin C Canine CRP fCAL® fPELA® CoV-2 Ab <100M 2006 2012 2015 2019 2020 2021 Year of first sales Renal Inflammation Inflammation Inflammation Pancreatic Cardiac & Infection & Infection elastase Seve
Slide 7: Sales model
Sales model Global Healthcare providers Distributors Diagnostics Companies - In selected markets we do not - Key relationships and larger - OEM partnerships to secure broad serve directly institutions in selected markets roll-out and acceptance of product
Slide 8: Sales and revenues
Sales and revenues Sales revenues - geographic split MNOK 2Q20 2Q19 1H20 1H19 US 1.0 0.6 1.7 1.1 Europe 9.9 7.7 21.1 15.1 Asia 5.7 1.9 10.1 4.6 Total 16.6 10.2 32.9 20.8 Sales revenues - product split MNOK 2Q20 2Q19 1H20 1H19 Cystatin C 8.5 3.9 15.0 8.6 fCAL® turbo 3.9 3.0 9.2 6.9 Other 4.3 3.3 8.7
Slide 9: Financial highlights 1H 2020
Financial highlights 1H 2020 MNOK 1H 2020 1H 2019 Sales 32.9 20.8 Other Revenues 6.1 3.4 Total Revenues 39.0 24.2 COGS 16.2 12.0 R&D Costs 10.7 9.3 SG&A 17.5 14.6 Capitalization -0.6 -1.4 OPEX 43.7 34.6 EBITDA -4.7 -10.4 EBIT -7.8 -27.9
Slide 10: Cash flow and cash position
Cash flow and cash position MNOK 2Q20 1Q20 2019 Operating activities 1.1 - 9.7 - 23.1 Investing activities - 1.2 - 0.4 - 4.7 Financing activities - 0.1 - 0.1 0.7 Changes in cash and cash equivalent - 0.2 - 10.2 -27.1 Cash and cash equivalent at the beginning of period 161.4 171.6 198.6 Cash and cash
Slide 11: CoV-2 Ab
CoV-2 Ab The first turbidimetric antibody/serology test for SARS-CoV-2 11
Slide 12: The alternative to closed system immunochemical SARS-CoV-2 serology testing
The alternative to closed system immunochemical SARS-CoV-2 serology testing Open system turbidimetric SARS-CoV-2 antibody testing for clinical chemistry analysers High throughput and efficient workflow with a cost-effective assay Addressing segments of immune status screening of the population
Slide 13: G-1001 Fast and accurate cardiovascular testing
G-1001 Fast and accurate cardiovascular testing 13
Slide 14: G-1001 – cardiac marker designed for high volume clinical chemistry platforms
G-1001 – cardiac maker designed for high volume clinical chemistry platforms Improved workflow and diagnostic efficiency in diagnosis of cardiac diseases Immunossay to be run on open clinical chemistry analysers independent of the platform provider No biotin interference, a common problem for
Slide 15: Performance data of Gentian PETIA assay – correlation between clinical analyzers
Performance data of Gentian PETIA assay – correlation between clinical analyzers The graph below shows the correlation between the same patient samples measured on the Mindray BS400 and Abbott Architect c4000 clinical analyzers (same reagents and calibrators used on both instruments). This is the fi
Slide 16: Summary
Summary Technology innovator with global footprint Customers benefit from product solutions for diagnostic efficiency Double digit sales growth Targeted investments to secure future ambitions Current business plan is fully funded
Slide 17: Get in touch with us
Get in touch with us www.gentian.com – info@gentian.com HQ GENTIAN AS Bjørnåsveien 5, 1596 Moss, Norway GENTIAN DIAGNOSTICS AB Kungsgatan 8, 111 43 Stockholm, Sweden GENTIAN USA INC. 215 N Eola Dr, Orlando, Florida US BEIJING REP. OFFICE Chaoyangmen Outer St Jia No.10 Chaoyang District, Beijing, Chi
Gentian Diagnostics — Pareto Healthcare Conference 2020 on 6ix